Macular Edema Clinical Trial
Official title:
Ozurdex in Treatment of Macular Edema Post Membrane Peeling
Verified date | May 2015 |
Source | Retina Specialists, PC |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
An epiretinal membrane is scar tissue on the retina that can cause blurring and distortion
of vision and lead to swelling, or macular edema. Despite surgery to remove the scar
tissue(membrane peeling), residual swelling of the retina may continue to interfere with
vision.
In this study the investigators will inject an implantable steroid device into the back,
fluid-filled portion of the eye. Steroids have been found to decrease the swelling in the
retina. Ozurdex™ is an implantable steroid. Once implanted, Ozurdex™ is slowly dissolved by
the vitreous gel that fills the eye, releasing the steroid. The steroid drug delivery system
in this study, known as Ozurdex™ has been FDA-approved by the US Food and Drug
Administration (FDA) for decreasing swelling due to another condition in the eye. This study
will help to find out whether or not this device Ozurdex™ is also effective for reducing the
swelling of the retina in patients who have already had surgery to remove scar tissue on the
retina.
Status | Completed |
Enrollment | 35 |
Est. completion date | April 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria - Patients with macular edema who have had previous epi-retinal membrane peeling surgery for macular edema associated with epi-retinal membranes. - All patients must have clear ocular media/lenses determined visually by the investigator in order to permit good quality stereoscopic fundus photography, fluorescein angiography and ocular coherence tomography. Exclusion Criteria: - Best corrected visual acuity 20/50 or better in the study eye - Sub-macular hemorrhage in the study eye - Sub-retinal fibrosis in the study eye - Macular hole in the study eye - Active inflammatory disease of the study eye - Choroidal neovascularization in the study eye - History of other ophthalmic disorders with the exception of cataract or previous cataract extraction in the study eye - Active ocular infection in the study eye - Previous subfoveal laser treatment in the study eye - Previous verteporfin photodynamic therapy in the study eye - Any systemic medical condition that would preclude them from undergoing surgery with monitored sedation. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Retina Specialists PC | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Retina Specialists, PC | Allergan |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | mean best corrected visual acuity as measured by Snellen visual acuity compared to enrollment | 6 months | Yes | |
Secondary | mean decrease in area and or volume of central foveal thickness as measured by OCT compared to enrollment | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04292912 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
|
Phase 1 | |
Recruiting |
NCT05976139 -
Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies
|
N/A | |
Completed |
NCT03660345 -
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
|
Phase 3 | |
Completed |
NCT03660371 -
ILM Peeling in PDR Patients Undergoing PPV for VH
|
N/A | |
Completed |
NCT01660802 -
Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)
|
Phase 3 | |
Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
Completed |
NCT04592419 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Completed |
NCT02623673 -
Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema
|
N/A | |
Terminated |
NCT01946399 -
Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
|
N/A | |
Completed |
NCT01428388 -
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
|
N/A | |
Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
Recruiting |
NCT01023113 -
To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation
|
N/A | |
Terminated |
NCT00918554 -
Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis
|
Phase 4 | |
Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT00970957 -
Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion
|
Phase 3 | |
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Completed |
NCT00411970 -
20- Versus 23- Gauge System for Pars Plana Vitrectomy
|
Phase 4 | |
Completed |
NCT00668239 -
Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser
|
N/A | |
Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 |